Quick Answer
Skye Bioscience, Inc. reported Operating Income Loss of -$58.16 million for the year ending 2025.
- Skye Bioscience, Inc. showed a decrease of -92.6% in Operating Income Loss from 2024 to 2025.
- This data is from Skye Bioscience, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2012 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$1.2 thousand | Q1 2014: -$30.1 thousand | Q2 2014: -$13.4 thousand | Q2 2014: -$142.9 thousand | Q3 2014: $4.1 thousand | Q3 2014: -$857.6 thousand | Q1 2015: -$909.8 thousand | Q2 2015: -$1.36 million | Q3 2015: -$896.3 thousand | Q1 2016: -$1.22 million | Q2 2016: -$1.48 million | Q3 2016: -$856.1 thousand | Q1 2017: -$1.38 million | Q2 2017: -$730.9 thousand | Q3 2017: -$761.6 thousand | Q1 2018: -$1.25 million | Q2 2018: -$1.08 million | Q3 2018: -$1.05 million | Q1 2019: -$1.52 million | Q2 2019: -$1.77 million | Q3 2019: -$1.50 million | Q1 2020: -$2.21 million | Q2 2020: -$1.22 million | Q3 2020: -$1.54 million | Q1 2021: -$1.74 million | Q2 2021: -$1.83 million | Q3 2021: -$1.82 million | Q1 2022: -$2.89 million | Q2 2022: -$3.22 million | Q3 2022: -$2.92 million | Q1 2023: -$3.10 million | Q2 2023: -$2.84 million | Q3 2023: -$24.71 million | Q1 2024: -$6.15 million | Q2 2024: -$8.41 million | Q3 2024: -$4.97 million | Q1 2025: -$11.76 million | Q2 2025: -$18.24 million | Q3 2025: -$13.26 million.
- Over the full 15 years of available data (2012 to 2025), Skye Bioscience, Inc.'s Operating Income Loss has declined by 1,412,865.7%.
- Historical annual values: Fiscal year 2025: -$58.16 million | Fiscal year 2024: -$30.19 million | Fiscal year 2023: -$34.74 million | Fiscal year 2022: -$18.31 million | Fiscal year 2021: -$7.85 million | Fiscal year 2020: -$6.29 million | Fiscal year 2019: -$6.63 million | Fiscal year 2018: -$4.69 million | Fiscal year 2017: -$3.86 million | Fiscal year 2016: -$4.47 million | Fiscal year 2015: -$4.32 million | Fiscal year 2014: -$2.73 million | Fiscal year 2013: -$120.4 thousand | Fiscal year 2013: -$7.2 thousand | Fiscal year 2012: $4.1 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: